These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 176180)

  • 21. Sequential alterations in the hepatic content and metabolism of cyclic AMP and cyclic GMP induced by DL-ethionine: evidence for malignant transformation of liver with a sustained increase in cyclic AMP.
    DeRubertis FR; Craven PA
    Metabolism; 1976 Dec; 25(12):1611-25. PubMed ID: 186692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of adenylate cyclase in perfusion mouse palate by secalonic acid D.
    Reddy RV; Eldeib MM; Reddy CS
    J Toxicol Environ Health; 1994 Feb; 41(2):175-85. PubMed ID: 8301697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of phosphodiesterase in the refractoriness of the Sertoli cell.
    Conti M; Toscano MV; Petrelli L; Geremia R; Stefanini M
    Endocrinology; 1983 Nov; 113(5):1845-53. PubMed ID: 6313332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of glucagon-mediated increases in hepatic cyclic adenosine 3', 5'-monophosphate by prostaglandin E1 and E2.
    DeRubertis FR; Zenser TV; Curnow RT
    Endocrinology; 1974 Jul; 95(1):93-101. PubMed ID: 4365622
    [No Abstract]   [Full Text] [Related]  

  • 25. Contribution by the glycogen pool and adenosine 3',5'-monophosphate release to the evanescent effect of glucagon on hepatic glucose production in vitro.
    Komjati M; Breitenecker F; Bratusch-Marrain P; Gampe J; Vierhapper H; Troch I; Waldhäusl W
    Endocrinology; 1985 Mar; 116(3):978-86. PubMed ID: 2578952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for delayed development of the glucagon receptor of adenylate cyclase in the fetal and neonatal rat heart.
    Clark CM; Beatty B; Allen DO
    J Clin Invest; 1973 May; 52(5):1018-25. PubMed ID: 4349483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of prostaglandins on hepatic adenylate cyclase activity and cyclic adenosine 3',5',-monophosphate content.
    Zenser TV; DeRubertis FR; Curnow RT
    Endocrinology; 1974 May; 94(5):1404-10. PubMed ID: 4362972
    [No Abstract]   [Full Text] [Related]  

  • 28. Decreased potency of glucagon on transformed-induced MDCK cells does not reflect an alteration of adenylate cyclase components.
    Beckner SK; Wright DE; Lin MC
    Endocrinology; 1987 Oct; 121(4):1438-46. PubMed ID: 3653036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of glucagon effects by changes in extracellular pH and calcium.
    Morand C; Remesy C; Demigne C
    Biochim Biophys Acta; 1988 Feb; 968(2):192-202. PubMed ID: 2829979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncoupling of the glucagon receptor-adenylate cyclase system by glucagon in cloned differentiated rat hepatocytes.
    Reilly T; Beckner S; Blecher M
    J Recept Res; 1980; 1(2):277-311. PubMed ID: 6271954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ontogeny of hepatic insulin and glucagon receptors and adenylate cyclase in rabbit.
    Ganguli S; Sinha MK; Sterman B; Harris P; Sperling MA
    Am J Physiol; 1983 Jun; 244(6):E624-31. PubMed ID: 6305205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A decreased response of cyclic adenosine monophosphate concentrations to glucagon in liver slices from streptozotocin-induced diabetic rats.
    Yamashita K; Yamashita S; Yasuda H; Oka Y; Ogata E
    Diabetes; 1980 Mar; 29(3):188-92. PubMed ID: 6247231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressin and angiotensin control the activity of liver phosphodiesterase.
    Keppens S; De Wulf H
    Biochem J; 1984 Aug; 222(1):277-80. PubMed ID: 6089761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of hepatic protein kinase activity by indomethacin.
    Ganguli S; Sterman B; Harris PS; Sinha MK; Banach WJ
    Metabolism; 1984 Sep; 33(9):845-52. PubMed ID: 6088943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon and cyclic AMP: time to turn the page?
    Rodgers RL
    Curr Diabetes Rev; 2012 Sep; 8(5):362-81. PubMed ID: 22587514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis.
    Francavilla A; Jones AF; Starzl TE
    Gastroenterology; 1978 Dec; 75(6):1026-32. PubMed ID: 213345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tadalafil inhibits the cAMP stimulated glucose output in the rat liver.
    Vilela VR; de Oliveira AL; Comar JF; Peralta RM; Bracht A
    Chem Biol Interact; 2014 Sep; 220():1-11. PubMed ID: 24911673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of glucagon as a contributor to glucose intolerance in acute and chronic uremia.
    Mondon CE; Marcus R; Reaven GM
    Metabolism; 1982 Apr; 31(4):374-9. PubMed ID: 7078421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signal transduction mechanism for glucagon-induced
    Yan AF; Chen T; Chen S; Tang DS; Liu F; Jiang X; Huang W; Ren CH; Hu CQ
    Int J Biol Sci; 2016; 12(12):1544-1554. PubMed ID: 27994518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perifused precision-cut liver slice system for the study of hormone-regulated hepatic glucose metabolism.
    McKee RL; Hruby VJ; Trivedi DB; Johnson DG; Gandolfi AJ; Krumdieck CL; Brendel K
    J Pharmacol Methods; 1988 Jul; 19(4):339-54. PubMed ID: 2840533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.